Combination of serum markers related to several mechanisms in Alzheimer's disease

Neurobiology of Aging

Volumn 24, Issue 7, 2003, Pages 893-902

  Teunissen, C E ^a,i   Lutjohann D ^b   Von Bergmann, K ^b   Verhey, F ^c   Vreeling, F ^c   Wauters, A ^d   Bosmans, E ^e   Bosma, H ^a   Van Boxtel, M P J ^a   Maes, M ^a   Delanghe, J ^f   Blom, H J ^g   Verbeek, M M ^g   Rieckmann, P ^h   De Bruijn, C ^a   Steinbusch, H W M ^a   De Vente, J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MIDDELHEIM HOSPITAL   (Belgium)

^e DiaMed EuroGen   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Cholesterol homeostasis; Combined marker analysis; Homocysteine; Inflammation; Serum

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; CYSTEINE; HOMOCYSTEINE; INTERLEUKIN 6 RECEPTOR; PHYTOSTEROL; PROTEIN; STEROL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HOMEOSTASIS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MOLECULE; PATHOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0043092171     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00005-8     Document Type: Article

References (47)

1. Anderson C., Checkoway H., Franklin G.M., Beresford S., Smith-Weller T., Swanson P.D. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov. Disord. 14(1):1999;21-27.
2. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B.et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58(3):2001;373-379.
3. Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B.et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 273(1):1999;5-8.
4. Angelis P., Scharf S., Mander A., Vajda F., Christophidis N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci. Lett. 244(2):1998;106-108.
5. Bonaccorso S., Lin A., Song C., Verkerk R., Kenis G., Bosmans E.et al. Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer's disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milano). 10(4):1998;316-323.
6. Bretillon L., Lütjohann D., Stahle L., Widhe T., Bindl L., Eggertsen G.et al. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J. Lipid Res. 41(5):2000;840-845.
7. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., Ueland P.M. Folate, Vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 55(11):1998;1449-1455.
8. Cullen K.M. Perivascular astrocytes within Alzheimer's disease plaques. Neuroreport. 8(8):1997;1961-1966.
9. Dierynck I., Bernard A., Roels H., De Ley M. Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16. Am. J. Respir. Cell Mol. Biol. 12(2):1995;205-210.
10. Dierynck I., Bernard A., Roels H., De Ley M. The human Clara cell protein: biochemical and biological characterisation of a natural immunosuppressor. Mult. Scler. 1(6):1996;385-387.
11. Eikelenboom P., Rozemuller A.J., Hoozemans J.J., Veerhuis R., van Gool W.A. Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis. Assoc. Disord. 14(Suppl. 1):2000;S54-S61.
12. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P.et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 10:2001;10.
13. Fink P.C., Romer M., Haeckel R., Fateh-Moghadam A., Delanghe J., Gressner A.M.et al. Measurement of proteins with the Behring Nephelometer. A multicentre evaluation. J. Clin. Chem. Clin. Biochem. 27(4):1989;261-276.
14. Galasko D. CSF tau and Abeta42: logical biomarkers for Alzheimer's disease? Neurobiol. Aging. 19(2):1998;117-119.
15. Giometto B., Argentiero V., Sanson F., Ongaro G., Tavolato B. Acute-phase proteins in Alzheimer's disease. Eur. Neurol. 28(1):1988;30-33.
16. Grundy S.M. George Lyman Duff Memorial Lecture. Multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease. Arterioscler. Thromb. 11(6):1991;1619-1635.
17. Hampel H., Teipel S.J., Padberg F., Haslinger A., Riemenschneider M., Schwarz M.J.et al. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. Brain Res. 823(1/2):1999;104-112.
18. Heafield M.T., Fearn S., Steventon G.B., Waring R.H., Williams A.C., Sturman S.G. Plasma cysteine and sulphate levels in patients with motor neurone Parkinson's and Alzheimer's disease. Neurosci. Lett. 110(1/2):1990;216-220.
19. Hellenbrand W., Seidler A., Boeing H., Robra B.P., Vieregge P., Nischan P.et al. Diet and Parkinson's disease. I. A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 47(3):1996;636-643.
20. Herrmann M., Vos P., Wunderlich M.T., de Bruijn C.H., Lamers K.J. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 31(11):2000;2670-2677.
21. Jolles J, Houx PJ, van Boxtel MPJ, Ponds RWHM. The Maastricht Aging Study. Determinants of cognitive aging. Maastricht: Neuropsych Publishers; 1995. p. 192.
22. Jones P.J. Cholesterol-lowering action of plant sterols. Curr. Atheroscler. Rep. 1(3):1999;230-235.
23. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H.et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 44(1):1998;17-26.
24. Langlois M.R., Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42(10):1996;1589-1600.
25. Lanzrein A.S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor- alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 12(3):1998;215-227.
26. Law M. Plant sterol and stanol margarines and health. BMJ. 320(7238):2000;861-864.
27. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C.et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103(1):2000;97-102.
28. Lütjohann D., Papassotiropoulos A., Bjorkhem I., Locatelli S., Bagli M., Oehring R.D.et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41(2):2000;195-198.
29. Maes M., DeVos N., Wauters A., Demedts P., Maurits V.W., Neels H.et al. Inflammatory markers in younger vs. elderly normal volunteers and in patients with Alzheimer's disease. J. Psychiatr. Res. 33(5):1999;397-405.
30. McCaddon A., Davies G., Hudson P., Tandy S., Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatr. 13(4):1998;235-239.
31. Miller J.W., Shukitt-Hale B., Villalobos-Molina R., Nadeau M.R., Selhub J., Joseph J.A. Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol. 20(1):1997;55-66.
32. Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R.et al. 24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36(1):2002;27-32.
33. Papassotiropoulos A., Lütjohann D., Bagli M., Locatelli S., Jessen F., Rao M.L.et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport. 11(9):2000;1959-1962.
34. Pirttila T., Mehta P.D., Frey H., Wisniewski H.M. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging. 15(3):1994;313-317.
35. Pratico D., Clark C.M., Liun F., Lee V.Y., Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59(6):2002;972-976.
36. Rieckmann P., Turner T., Kligannon P., Steinhoff B.J. Telencephalin as an indicator for temporal-lobe dysfunction. Lancet. 352(9125):1998;370-371.
37. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R.et al. Use of lipid-lowering agents indication bias and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59(2):2002;223-227.
38. Roher A.E., Weiss N., Kokjohn T.A., Kuo Y.M., Kalback W., Anthony J.et al. Increased Abeta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry. 41(37):2002;11080-11090.
39. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B.et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346(7):2002;476-483.
40. Siest G., Bertrand P., Qin B., Herbeth B., Serot J.M., Masana L.et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin. Chem. Lab. Med. 38(8):2000;721-730.
41. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A.et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 88(23):1991;10540-10543.
42. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S.et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90(5):1993;1977-1981.
43. Teunissen C.E., de Vente J., Steinbusch H.W.M., De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging. 23(4):2002;485-508.
44. Teunissen C.E., de Vente J., von Bergmann K., Bosma H., van Boxtel M.P.J., De Bruijn C. Serum cholesterol. Neurobiol. Aging. 24(1):2003;147-155.
45. Ujiie M., Dickstein D.L., Jefferies W.A. p97 as a biomarker for Alzheimer disease. Front Biosci. 7:2002;E42-E47.
46. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57(10):2000;1439-1443.
47. Working-Group. Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19(2):109-16.